We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck announced good sales growth for the last quarter of 2006 but noted a major drop in earnings due to special charges and an increase in reserves for future legal costs.
Wyeth announced an increase of 17 percent in fourth quarter earnings, after sales of five pharmaceutical products reached more than $1 billion each in 2006.
A recent article and editorial in the Annals of Family Medicine criticizing direct-to-consumer (DTC) advertising prompted a strong rebuttal from industry groups.
Schering-Plough’s fourth quarter profits for 2006 rose 75 percent from the same time period in 2005, and its net income for the same period was $182 million, up from $104 million in the fourth quarter of 2005, the company announced.
Amgen reported a strong increase in sales for 2006, although the company’s profit for the fourth quarter increased only 1 percent from the same time period in 2005.
The NIH is placing greater emphasis on bringing new researchers into the R&D pipeline and rewarding more productive labs to make the most of what is likely a flat budget in fiscal 2008, a high-ranking agency official says.
The Washington Legal Foundation (WLF) is supporting a former regulatory affairs official’s appeal of a recent court ruling that he conspired to sell a device that had not been approved by the FDA.
Bristol-Myers Squibb (BMS) reported a net loss from continuing operations of $134 million on sales of $4.2 billion in the fourth quarter of 2006, compared with net earnings of $499 million on sales of $5 billion for the same period in 2005.
Keeping up with state drug marketing laws will be a challenge for companies but should get easier with time as the laws become more uniform, industry experts said at an FDAnews audioconference.